Clinical characteristics and outcomes of phase I cancer patients with CCNE1 amplification: MD Anderson experiences
出版年份 2022 全文链接
标题
Clinical characteristics and outcomes of phase I cancer patients with CCNE1 amplification: MD Anderson experiences
作者
关键词
-
出版物
Scientific Reports
Volume 12, Issue 1, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2022-05-24
DOI
10.1038/s41598-022-12669-5
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for TP53 mutant malignancies
- (2020) Yudong Wang et al. Scientific Reports
- CCNE1 Amplification as a Predictive Biomarker of Chemotherapy Resistance in Epithelial Ovarian Cancer
- (2020) Justin W. Gorski et al. Diagnostics
- CCNE1 amplification is associated with poor prognosis in patients with triple negative breast cancer
- (2019) Zi-Ming Zhao et al. BMC CANCER
- Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor–Positive Metastatic Breast Cancer
- (2019) Nicholas C. Turner et al. JOURNAL OF CLINICAL ONCOLOGY
- Validation of a Plasma-Based Comprehensive Cancer Genotyping Assay Utilizing Orthogonal Tissue- and Plasma-Based Methodologies
- (2018) Justin I. Odegaard et al. CLINICAL CANCER RESEARCH
- Cyclin E1 and cyclin-dependent kinase 2 are critical for initiation, but not for progression of hepatocellular carcinoma
- (2018) Roland Sonntag et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Outcome analysis of Phase I trial patients with metastatic KRAS and/or TP53 mutant non-small cell lung cancer
- (2018) Yudong Wang et al. Oncotarget
- Cyclin-Dependent Kinase 2 Inhibitors in Cancer Therapy: An Update
- (2018) Solomon Tadesse et al. JOURNAL OF MEDICINAL CHEMISTRY
- Antiangiogenesis and gene aberration-related therapy may improve overall survival in patients with concurrent KRAS and TP53 hotspot mutant cancer
- (2017) Zhijie Wang et al. Oncotarget
- CCNE1 copy-number gain and overexpression identify ovarian clear cell carcinoma with a poor prognosis
- (2016) Ayse Ayhan et al. MODERN PATHOLOGY
- Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation
- (2015) S. Fu et al. ANNALS OF ONCOLOGY
- CCNE1 amplification is associated with aggressive potential in endometrioid endometrial carcinomas
- (2015) KENTARO NAKAYAMA et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Cyclin-dependent kinase 2 is an ideal target for ovary tumors with elevated cyclin E1 expression
- (2015) Liu Yang et al. Oncotarget
- Cyclin E amplification/overexpression is associated with poor prognosis in gastric cancer
- (2014) M. Alsina et al. ANNALS OF ONCOLOGY
- Cyclin E involved in early stage carcinogenesis of esophageal adenocarcinoma by SNP DNA microarray and immunohistochemical studies
- (2014) Zhongren Zhou et al. BMC GASTROENTEROLOGY
- Clinical massively parallel next-generation sequencing analysis of 409 cancer-related genes for mutations and copy number variations in solid tumours
- (2014) R R Singh et al. BRITISH JOURNAL OF CANCER
- “Platinum resistant” ovarian cancer: What is it, who to treat and how to measure benefit?
- (2014) Alison Davis et al. GYNECOLOGIC ONCOLOGY
- MEK inhibition in non-small cell lung cancer
- (2014) Thomas E. Stinchcombe et al. LUNG CANCER
- Cyclin E1 Deregulation Occurs Early in Secretory Cell Transformation to Promote Formation of Fallopian Tube-Derived High-Grade Serous Ovarian Cancers
- (2013) A. M. Karst et al. CANCER RESEARCH
- Resistance to CDK2 Inhibitors Is Associated with Selection of Polyploid Cells in CCNE1-Amplified Ovarian Cancer
- (2013) D. Etemadmoghadam et al. CLINICAL CANCER RESEARCH
- Cyclin E1 (CCNE1) as independent positive prognostic factor in advanced stage serous ovarian cancer patients – A study of the OVCAD consortium
- (2013) Dietmar Pils et al. EUROPEAN JOURNAL OF CANCER
- Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
- (2013) J. Gao et al. Science Signaling
- Potential tumorigenic programs associated with TP53 mutation status reveal role of VEGF pathway
- (2012) H Joshi et al. BRITISH JOURNAL OF CANCER
- Meta-analysis for cyclin E in lung cancer survival
- (2012) Li-nian Huang et al. CLINICA CHIMICA ACTA
- Survival of 1,181 Patients in a Phase I Clinic: The MD Anderson Clinical Center for Targeted Therapy Experience
- (2012) J. Wheler et al. CLINICAL CANCER RESEARCH
- Cyclin-Dependent Kinase Suppression by WEE1 Kinase Protects the Genome through Control of Replication Initiation and Nucleotide Consumption
- (2012) H. Beck et al. MOLECULAR AND CELLULAR BIOLOGY
- Value of integrated positron emission tomography revised using a phantom study to evaluate malignancy grade of lung adenocarcinoma
- (2010) Haruhiko Nakayama et al. CANCER
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
- (2010) Yung-Jue Bang et al. LANCET
- Serous tubal intraepithelial carcinoma upregulates markers associated with high-grade serous carcinomas including Rsf-1 (HBXAP), cyclin E and fatty acid synthase
- (2010) Ann Smith Sehdev et al. MODERN PATHOLOGY
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started